Trinseo ("Trinseo" or "the Company") (NYSE:TSE), a specialty material solutions provider, today announced that it has obtained $1.077 billion in aggregate principal amount of secured term loan financing ("New Term Loan

TSE

Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies

By Vandana Singh

November 29, 9:30 AM

Tuesday, the FDA said it received reports of patients developing T-cell malig

BMY

Disney Board Reached Out To Iger About Return On Friday

Related Posts

Goldman Sachs Downgrades Harmony Biosciences to Neutral, Announces $55 Price Target

FDA Says Teleflex Recalls Iso-Gard Filter S For Risk Of Splitting Or Detaching That May Cause Leakage And Insufficient Air Supply To Patients; FDA Says Has Identified Teleflex Recall Of Iso-Gard Filter S As A Class I Recall, Most Serious Type Of Recall

Trinseo Announces Completion Of Transaction To Refinance $660M 2024 Term Loan And $385M Of 2025 Senior Notes

Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies